Cafepharma Today

June 5 2025 - GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO
FDA’s Elsa AI is here, and the industry has questions
Merck gains U.S. patent office support in Keytruda dispute
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Clock Is Ticking For AstraZeneca
Forbes
Tuesday, February 25, 2014 - 3:57pm
tags:
AstraZeneca, dulaglutide, GSK, Eli Lilly, Bydureon, diabetes
One Reason the Biotech Boom Won’t Turn to Bust
Barron's
Tuesday, February 25, 2014 - 11:17am
tags:
biotech, Biogen Idec, Regeneron
Two Years Less Exclusivity Is the Least of Amarin's Issues
Motley Fool
Tuesday, February 25, 2014 - 11:15am
tags:
Amarin, exclusivity, Vascepa
No Looking Back for Regeneron's Eylea
Yahoo/Zacks.com
Tuesday, February 25, 2014 - 11:05am
tags:
Regeneron, Eylea, BRVO
Is NPS Pharmaceuticals The Next Alexion?
Seeking Alpha
Tuesday, February 25, 2014 - 11:03am
tags:
NPS Pharmaceuticals, Alexion, NPSP795, Gattex
Wright Medical Group Sees Wider Q4 Loss
Yahoo/Zacks.com
Tuesday, February 25, 2014 - 11:00am
tags:
earnings, Wright Medical
Zerenex For The Treatment Of Hyperphosphatemia: A New Use For An Old Compound
Seeking Alpha
Tuesday, February 25, 2014 - 10:59am
tags:
hyperphosphatemia, Zerenex, Keryx
DARA BioSciences' KRN5500 Receives Orphan Drug Designation From FDA
Yahoo/Benzinga
Tuesday, February 25, 2014 - 10:51am
tags:
DARA Biosciences, KRN5500, FDA, orphan drugs, chronic chemotherapy-induced peripheral neuropathy
Endocyte's Q4 Loss Narrower than Expected
Yahoo/Zacks.com
Tuesday, February 25, 2014 - 10:49am
tags:
Endocyte, earnings
FDA approves Bristol-Myers drug for rare body fat disorder
Yahoo/Reuters
Tuesday, February 25, 2014 - 10:47am
tags:
FDA, Bristol-Myers Squibb, lipodystrophy, Myalept
Novartis looks for businesses to achieve scale, WSJ reports
Yahoo/Fly on the Wall
Tuesday, February 25, 2014 - 8:47am
tags:
Novartis, M&A
Lilly weekly diabetes drug succeeds vs market leader Victoza -study
Yahoo/Reuters
Tuesday, February 25, 2014 - 8:15am
tags:
Eli Lilly, diabetes, Victoza, Novo Nordisk, dulaglutide
InterMune Hits Home Run With Pivotal Lung Drug Study Results
TheStreet.com
Tuesday, February 25, 2014 - 8:14am
tags:
InterMune, pirfenidone, IPF, idiopathic pulmonary fibrosis
Verastem acquires the license to VS-4718 originally held by Poniard
Yahoo/Fly on the Wall
Tuesday, February 25, 2014 - 7:38am
tags:
Verastem, VS-4718, Poniard, stem cells
Ranbaxy halts drug ingredient shipments from two plants as scrutiny mounts
Yahoo/Reuters
Tuesday, February 25, 2014 - 7:29am
tags:
India, Ranbaxy, drug manufacturing
Public Citizen says FDA should add heart warning to popular testosterone drugs for men
Yahoo/AP
Tuesday, February 25, 2014 - 7:27am
tags:
FDA, testosterone, Public Citizen, Androgel, Androderm, Fortesta, Axiron, Watson Pharmaceuticals, AbbVie, Eli Lilly, Endo Health Solutions
Pharmaceutical Strength Expected To Continue With Questcor Tuesday
Seeking Alpha
Tuesday, February 25, 2014 - 7:25am
tags:
earnings, Questcor
3 Things to Watch at Gilead
Motley Fool
Tuesday, February 25, 2014 - 7:24am
tags:
Gilead Sciences, Sovaldi, HIV, hepatitis C
Can Horizon Pharma (HZNP) Run Higher on Strong Earnings Estimate Revisions?
Yahoo/Zacks.com
Tuesday, February 25, 2014 - 7:23am
tags:
Horizon Pharma, earnings
5 Pharmas Spending the Most to Develop Drugs: Merck, AstraZeneca, Roche, Bristol, and Lilly
Motley Fool
Tuesday, February 25, 2014 - 7:22am
tags:
Merck, AstraZeneca, Roche, Bristol-Myers Squibb, Eli Lilly, R&D, drug development

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Not One of Your Easy Crystals
In the Pipeline
The Continuing Crisis, Part XV: The Horrendous Trump Budget
In the Pipeline
Taurine Revisited
In the Pipeline
A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.